DDAVP (desmopressin acetate) by Ferring Pharmaceuticals is clinical pharmacology ddavp tablets contain as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. Approved for primary nocturnal enuresis. First approved in 1995.
Drug data last refreshed 15h ago · AI intelligence enriched 4d ago
DDAVP (desmopressin acetate) is a synthetic analogue of arginine vasopressin that works as an antidiuretic agent by enhancing water reabsorption in the kidneys. It is primarily indicated for primary nocturnal enuresis and central diabetes insipidus, reducing urinary frequency and nocturia to enable a more normal lifestyle. The oral tablet formulation has low bioavailability (~5% vs intranasal) but provides sustained antidiuretic effects lasting up to 12 hours at higher doses.
As LOE approaches, brand team is likely consolidating and focusing on lifecycle extension or preparing for generic transition, signaling potential headcount restructuring.
CLINICAL PHARMACOLOGY DDAVP Tablets contain as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. Central Diabetes Insipidus Dose response studies in patients with diabetes insipidus have demonstrated that oral doses of 0.025 mg to 0.4 mg…
Worked on DDAVP at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
The Effect of Combined Systematized Behavioural Modification Education Program (SyBeMeP) With DDAVP in Patients With Nocturia
Desmopressin Acetate 0.2 mg Tablets, Fasting
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDDAVP represents a mature, legacy product with zero linked job openings, indicating limited hiring and career mobility. Working on this product offers stability in established markets but minimal growth trajectory, making it less attractive for career advancement compared to growth-stage therapeutics.